Elevated LINC01232 is associated with poor prognosis and HBV infection in hepatocellular carcinoma patients and contributes to tumor progression in vitro - 27/03/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | LINC01232 reduction inhibited HCC cells proliferation, migration and invasion. |
• | LINC01232 expression was significantly correlated with HBV infection in HCC. |
• | LINC01232 showed potential to distinguish HBV-infected HCC patients. |
• | High LINC01232 may be a biomarker to indicate survival prognosis in HCC patients. |
• | LINC01232 plays as an oncogene in HCC progression, which may exert by sponging miR-708-5p. |
Abstract |
Background |
Hepatocellular carcinoma (HCC) had high prevalence and poor prognosis, and hepatitis B virus (HBV) infection is a major risk factor. The aim of this study is to analyze the role of long intergenic noncoding RNA 01232 (LINC01232) in the prognosis and progression of HCC, and explore the relationship between LINC01232 and HBV infection.
Methods |
LINC01232 expression and its prognostic value were firstly analyzed using TCGA database. Quantitative real-time PCR was used to evaluate the expression of LINC01232 in HCC patients and cell lines. Kaplan-Meier curves were used to analyze the relationship between LINC01232 expression and HCC overall survival prognosis. Function-loss in vitro experiments were performed to demonstrate the role of LINC01232 in HCC progression. A luciferase reporter assay and Pearson correlation were used to confirm the relationship between LINC01232 and microRNA (miR)-708-5p in HCC.
Results |
The expression of LINC01232 was upregulated in HCC tissues and cell lines, and high LINC01232 was associated with worse overall survival in HCC. LINC01232 reduction inhibited HCC cells proliferation, migration and invasion. LINC01232 expression was significantly correlated with HBV infection and liver cirrhosis, and showed potential to distinguish HBV-infected HCC patients. miR-708-5p, as a HBV-related miRNA, was a potential target of LINC01232, and was negatively correlated with LINC01232 in HCC.
Conclusion |
Our findings found that highly expressed LINC01232 may be a biomarker to indicate survival prognosis in HCC patients, especially in HBV-infected cases. In addition, LINC01232 plays as an oncogene in HCC progression, and its function may exert by sponging miR-708-5p.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis B virus, Hepatocellular carcinoma, LINC01232, miR-708-5p, overall survival, prognosis, proliferation
Plan
Vol 46 - N° 3
Article 101813- mars 2022 Retour au numéro
Article précédent
- Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile
- Deng Wu, Renqian Zhang, Lei Zhan
- Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history
- Junjun Tang, Zongliang Huang, Jichong Xu, Qi Lv, Peijun Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?